Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different contrast agents—gadopiclenol and gadobutrol—that help doctors get clearer images during MRI scans of the kidneys and adrenal glands when there are unexpected findings. The main goal is to see if gadopiclenol works just as well as the standard agent, gadobutrol, in helping doctors make a diagnosis.

People who might join this study are adults aged 18 or older who need an MRI to look at unexpected kidney or adrenal gland findings, have a body weight and height that keeps their BMI under 31, and can safely have an MRI scan. Participants will be randomly placed into one of two groups: one group will receive gadopiclenol, and the other will get gadobutrol. Each person will know which contrast agent they receive before their MRI, which takes about an hour. It’s important to note that people who have implants that could affect the MRI, are claustrophobic, pregnant or breastfeeding, or have difficulty understanding the study won’t be able to participate. This study is not yet recruiting participants but aims to help improve how these scans are done in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • signed informed consent
• • age ≥18 years
• • compatibility with magnetic resonance imaging
• • planned workup of kidney incidental finding or adrenal incidental findings (or both)
• • body mass index (BMI) \< 31 kg/m2
• Exclusion Criteria:
• • patients with implants that might affect imaging parameters in the region under investigation, as judged by the principal investigator
• • vulnerable individuals
• • claustrophobic individuals
• • individuals that are cognitively impaired or unable to understand the language
• • pregnant or breastfeeding patients